Skip to main content

Table 2 Baseline demographic and clinical characteristics of tofacitinib-treated patients, overall and by prior biologic history

From: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

Demographics Overall Biologic-naïve 1 prior biologic ≥ 2 prior biologics
N = 225 N = 43 N = 92 N = 90
Duration of variable-length baseline period (years), mean (SD) 3.4 (1.8) 3.4 (1.9) 3.0 (1.8) 3.9 (1.8)
Age at index date (years), mean (SD) 45.6 (16.5) 46.5 (17.1) 45.5 (15.4) 45.2 (17.4)
Gender, n (%)
 Female 113 (50.2) 22 (51.2) 49 (53.3) 42 (46.7)
 Male 112 (49.8) 21 (48.8) 43 (46.7) 48 (53.3)
12-month baseline Charlson comorbidity score, mean (SD) 0.7 (1.3) 0.5 (1.0) 0.7 (1.5) 0.7 (1.2)
Prior biologic use, n (%)
 Adalimumab 101 (44.9) 0 (0.0) 44 (47.8) 57 (63.3)
 Infliximab 87 (38.7) 0 (0.0) 28 (30.4) 59 (65.6)
 Golimumab 27 (12.0) 0 (0.0) 4 (4.4) 23 (25.6)
 Vedolizumab 90 (40.0) 0 (0.0) 16 (17.4) 74 (82.2)
Number of unique biologics, n (%)
 0 43 (19.1) 43 (100.0) NA NA
 1 92 (40.9) NA 92 (100.0) NA
 2 64 (28.4) NA NA 64 (71.1)
   Vedolizumab + TNFi 49 (21.8) NA NA 49 (54.4)
   TNFi + TNFi 15 (6.7) NA NA 15 (16.7)
 ≥ 3 26 (11.6) NA NA 26 (28.9)
  1. n, number of patients in the specified category; N, number of patients in the treatment group; NA, not applicable; SD, standard deviation; TNFi, tumour necrosis factor inhibitor